Efficacy results across a 12-month double-blind randomized trial and an open-label extension phase of arimoclomol for treatment of Niemann-Pick disease type C in patients treated with miglustat
Tuesday, September 9, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses the efficacy results from a 12-month double-blind randomized trial and an open-label extension phase of arimoclomol for treating Niemann-Pick disease type C in patients already on miglustat. The findings were presented at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025. The study aims to provide insights into the treatment's effectiveness over an extended period.
Price reaction · baseline $8.33 (2025-09-08 close) · hit pre-market · 3 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
-1.4%
Market Sentiment Analysis
POSITIVE FACTORS
Efficacy results show promise for arimoclomol.
Study includes a significant duration of 12 months.
Open-label extension phase may enhance treatment understanding.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Efficacy results across a 12-month double-blind randomized trial and an open-label extension phase of arimoclomol for treatment of Niemann-Pick disease type C in patients treated with miglustat
International Congress of Inborn Errors of Metabolism (ICIEM) 2025 - 09/04/2025
Download PDF
Download PDF
Frequently Asked Questions
What was the duration of the trial for arimoclomol?
The trial lasted for 12 months.
What disease is arimoclomol being tested for?
Arimoclomol is being tested for Niemann-Pick disease type C.
What type of trial was conducted for arimoclomol?
A double-blind randomized trial was conducted.
Where were the findings presented?
The findings were presented at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025.